文章名稱引用次數(shù)

• Interrelationship of canonical and non-canonical Wnt signalling pathways in chronic metabolic diseases14
• Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?10
• Effects of sodium glucose co-transporter 2 inhibitors on the kidney9
• Microvascular complications among patients with diabetes: An emerging health problem in Saudi Arabia8
• Elevated circulating effector memory T cells but similar levels of regulatory T cells in patients with type 2 diabetes mellitus and cardiovascular disease7
• Effects of magnitude of visceral adipose tissue reduction: Impact on insulin resistance, hyperleptinemia and cardiometabolic risk in adolescents with obesity after long-term weight-loss therapy6
• Increased erythrocyte- and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus6
• Impact of diabetes type on treatment and outcome of patients with peripheral artery disease5
• Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial5
• Increased plasma FGF21 level as an early biomarker for insulin resistance and metabolic disturbance in obese insulin-resistant rats4